Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3109951 | 0.98 | LPL (0.56) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL659509 | 0.80 | HRH3 (0.82) | HRH3TSHRALDH1A1TAAR1NOS3 | |
| SCHEMBL7197772 | 0.79 | LPL (0.50) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL12663150 | 0.79 | LPL (0.50) | LPLLIPGCA2CA1TSHR | |
| SCHEMBL29954820 | 0.79 | ALDH1A1 (0.57) | LPLLIPGCA2CA1F11 | |
| SCHEMBL28451270 | 0.78 | LPL (0.59) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL2554733 | 0.78 | LPL (0.61) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL19697830 | 0.78 | PYCR1 (0.51) | LPLLIPGCA2CA1F11 | |
| Hydrochloric Acid SCHEMBL3337542 | 0.77 | LPL (0.57) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL4802780 | 0.77 | ENPP2 (0.48) | LPLLIPGCA2CA1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240173-B | Preparation process of high-strength polyurethane heat-insulating material | 优佰特(山东)新材料技术有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-118240173-A | Preparation process of high-strength polyurethane heat-insulating material | 优佰特(山东)新材料技术有限公司 | 2024-06-25 | — | — | CN | claimed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| US-20050261263-A1 | Benzoquinone ansamycins | KOSAN BIOSCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-6872715-B2 | Benzoquinone ansamycins | KOSAN BIOSCIENCES, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1420747-A2 | BENZOQUINONE ANSAMYCINS | Kosan Biosciences, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030114450-A1 | Anticancer agents; antiproliferative agent | KOSAN BIOSCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003013430-A2 | BENZOQUINONE ANSAMYCINS | KOSAN BIOSCIENCES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | LPL 2073/4885LIPG 2686/4885HRH3 756/4885 |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | LPL 175/4885LIPG 152/4885HRH3 3776/4885 |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LPL 4835/4885LIPG 4630/4885HRH3 2284/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | LPL 3745/4885LIPG 3349/4885HRH3 3600/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | LPL 3708/4885LIPG 1899/4885HRH3 2012/4885 |
| US-20030114450-A1 | Anticancer agents; antiproliferative agent | HSP90AB1, HSP90B1, HSP90AA1 | LPL 3713/4885LIPG 3634/4885HRH3 4253/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | LPL 2073/4885LIPG 2686/4885HRH3 756/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | LPL 4267/4885LIPG 3733/4885HRH3 3894/4885 |
| US-20050261263-A1 | Benzoquinone ansamycins | HSP90B1, HSP90AB1, HSP90AB2P | LPL 3841/4885LIPG 3774/4885HRH3 4148/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | LPL 2073/4885LIPG 2686/4885HRH3 756/4885 |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | LPL 2712/4885LIPG 3253/4885HRH3 240/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LPL 4835/4885LIPG 4630/4885HRH3 2284/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | LPL 2073/4885LIPG 2686/4885HRH3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.